Celcuity Inc. — Q3 2021 Form 10-Q Summary
Business context and reporting period
For the quarter and nine months ended September 30, 2021. Celcuity is a clinical-stage biotechnology company developing its CELsignia companion-diagnostic platform and targeted therapies. It reported no revenue to date and has not been profitable.
Key financial metrics
| Metric | Q3 2021 / September 30, 2021 | Comparable period / prior year-end |
|---|---|---|
| Revenue | None | None |
| Operating expenses | $5.60 million for Q3; $22.04 million for nine months | $2.48 million for Q3 2020; $7.00 million for nine months 2020 |
| Research and development | $4.96 million for Q3; $20.27 million for nine months | $1.96 million for Q3 2020; $5.58 million for nine months 2020 |
| Net loss | $6.03 million for Q3; $22.85 million for nine months; loss per share $0.41 and $1.78, respectively | $2.47 million for Q3 2020; $6.92 million for nine months 2020 |
| Cash and cash equivalents | $90.37 million | $11.64 million at December 31, 2020 |
| Operating cash flow | $(14.19) million for nine months | $(5.04) million for nine months 2020 |
| Debt | $15.0 million initial loan principal; $14.43 million carrying value, non-current | No note payable at December 31, 2020 |
| Balance sheet | Total assets $91.84 million; current liabilities $2.82 million; stockholders’ equity $74.47 million | At December 31, 2020: assets $12.96 million; current liabilities $1.19 million; equity $11.70 million |
No gross margin is reported because the company had no revenue.
Material changes versus the prior comparable period
- Q3 net loss increased 144% to $6.03 million; nine-month net loss increased 230% to $22.85 million.
- Nine-month R&D expense rose 263%, primarily reflecting the Pfizer gedatolisib license, including $10.0 million of upfront consideration ($5.0 million cash and $5.0 million in stock), plus drug development and clinical-trial costs.
- Cash increased substantially following two 2021 follow-on offerings, which together generated $78.5 million net, and the $15.0 million initial Innovatus loan tranche, which generated $14.35 million net of costs and discount.
- Shares issued and outstanding increased to 14.91 million from 10.30 million at year-end 2020. The July offering alone issued 2.25 million shares.
Outlook, commentary, and risks
- Management said existing cash should fund operations and obligations for at least the next 12 months, based on its current plan. It expects R&D and G&A spending to increase and anticipates future commercialization-related sales and marketing costs.
- Subject to FDA feedback, Celcuity planned to start a Phase 2/3 gedatolisib trial in ER-positive/HER2-negative advanced or metastatic breast cancer in the first half of 2022. The supporting Phase 1b results cited are preliminary.
- COVID-19 and Delta-variant-related hospitalizations delayed enrollment expectations for FACT-1 and FACT-2: interim results were expected in the second half of 2022, with final results about nine months later.
- The Innovatus facility permits up to $10 million in additional term loans, subject to milestones and deadlines. It is secured by substantially all company assets, has an effective interest rate of 11.36%, includes a minimum-cash requirement, and provides Innovatus a limited conversion right.
- The Pfizer license includes potential development and commercial milestone payments of up to $335 million and tiered royalties in the low-to-mid teens. These are contingent future obligations, not current-period expenses.
- Key risks include clinical and regulatory failure, dependence on financing and pharmaceutical partners, uncertain adoption and reimbursement of diagnostics, competition, and pandemic-related trial and research disruption. The filing reported no material legal proceedings and stated disclosure controls were effective.
Important facts for investors to verify
- Whether the planned gedatolisib Phase 2/3 trial began on schedule and what its design, funding needs, and regulatory path are.
- Updated, mature efficacy and safety results for gedatolisib; the cited Phase 1b results were preliminary and based on a January 2021 cutoff.
- Actual cash burn, runway, and whether the conditional Innovatus tranches or additional financing will be needed.
- Progress, enrollment, and updated timelines for the six CELsignia-selected Phase II collaborations, including COVID-related delays.
- Potential dilution and debt costs, including future warrant issuance, the lender’s conversion right, and Pfizer milestone and royalty obligations.